Recurrent Adult Brain Tumor Clinical Trial
Official title:
Phase II Trial of STI571 (NSC 716051) in Patients With Recurrent Meningioma
Phase II trial to study the effectiveness of imatinib mesylate in treating patients who have recurrent meningioma. Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth
PRIMARY OBJECTIVES:
I. Determine the efficacy of imatinib mesylate, in terms of 6-month progression-free
survival, of patients with recurrent meningioma.
II. Determine the response rate and overall survival of patients treated with this drug.
III. Evaluate the safety profile of this drug in these patients. IV. Determine the
pharmacokinetics of this drug in these patients. V. Determine the surrogate endpoints of
angiogenic activity of this drug in these patients.
VI. Correlate molecular abnormalities in the tumor with response in patients treated with
this drug.
OUTLINE: This is a multicenter study. Patients are stratified according to concurrent use of
enzyme-inducing antiepileptic drugs (yes vs no), histology (benign vs atypical or
malignant), neurofibromatosis positivity (yes vs no), and preoperative candidacy (yes vs
no).
Patients receive oral imatinib mesylate once or twice daily. Courses repeat every 4 weeks in
the absence of disease progression or unacceptable toxicity.
Patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 60 patients (30 per stratum) will be accrued for this study
within 8-12 months.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
| Completed |
NCT00238303 -
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
|
Phase 2 | |
| Completed |
NCT02015819 -
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
| Completed |
NCT00045708 -
A Phase I/II Trial of BMS-247550 for Treatment of Patients With Recurrent High-Grade Gliomas
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT03890952 -
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma
|
Phase 2 | |
| Terminated |
NCT01814813 -
Vaccine Therapy With Bevacizumab Versus Bevacizumab Alone in Treating Patients With Recurrent Glioblastoma Multiforme That Can Be Removed by Surgery
|
Phase 2 | |
| Terminated |
NCT01996527 -
3T MRI Biomarkers of Glioma Treatment Response
|
Early Phase 1 | |
| Terminated |
NCT01575275 -
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
|
Phase 2 | |
| Terminated |
NCT01103375 -
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
|
Phase 1 | |
| Completed |
NCT00459381 -
Pazopanib in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Terminated |
NCT00006773 -
Bortezomib in Treating Patients With Recurrent Glioma
|
Phase 1 | |
| Completed |
NCT00016328 -
CCI-779 in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 2 | |
| Completed |
NCT01806675 -
18F-FPPRGD2 PET/CT or PET/MRI in Predicting Early Response in Patients With Cancer Receiving Anti-Angiogenesis Therapy
|
Phase 1/Phase 2 | |
| Terminated |
NCT01148966 -
Aminolevulinic Acid During Surgery in Treating Patients With Malignant Brain Tumors
|
Phase 1 | |
| Completed |
NCT00492089 -
Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer
|
Phase 2 | |
| Completed |
NCT01125046 -
Bevacizumab in Treating Patients With Recurrent or Progressive Meningiomas
|
Phase 2 | |
| Completed |
NCT01894061 -
NovoTTF-100A With Bevacizumab (Avastin) in Patients With Recurrent Glioblastoma
|
Phase 2 | |
| Completed |
NCT01644955 -
Carboplatin in Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
| Terminated |
NCT01269411 -
RO4929097 in Treating Patients With Recurrent Invasive Gliomas
|
Phase 1 | |
| Completed |
NCT00641706 -
Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme
|
Phase 2 |